ClinicalTrials.gg
RecruitingNCT06471348Updated Oct 22, 2025

Postoperative Pain Control in AIS Using Liposomal Bupivacaine vs. 0.25% Bupivacaine With Epinephrine

An interventional study of Bupivacaine liposome injectable suspension and Bupivacaine Hydrochloride and Epinephrine Injection in Post Operative Pain and Spinal Fusion, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Planned enrollment
22nd of 93
128 · median 80
Started
2025
with 2 others
No phase
9 of 93
3 open now
Primary completion
2027-08
later than 10 of 14 live
Registered
84th of 93
by date

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 22nd largest by planned enrollment, is one of 3 that started in 2025, is one of 9 with no phase, reaches primary completion later than 10 of the 14 other live ones, and was the 84th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

A randomized controlled trial (RCT) investigating whether the local anesthetic injection of liposomal bupivacaine during posterior spinal fusion (PSF) for AIS is more effective in reducing acute postoperative opioid consumption compared to an equal volume injection of 0.25% bupivacaine with epinephrine for patients aged 10 to 17, with 128 patients randomly assigned to one of two arms: liposomal bupivacaine or 0.25% bupivacaine with epinephrine.

03

Conditions studied

  • Post Operative Pain
  • Spinal Fusion

Browse trials for

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥10 years old and ≤17 years old at assessment
  • Diagnosis of Adolescent Idiopathic Scoliosis
  • Planned surgical treatment of progressive spinal deformity with posterior spinal fusion

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of neuromuscular, syndromic, or congenital scoliosis
  • History of known allergy to local anesthesia
  • Chronic pre-operative opioid consumptions
  • Any other analgesic treatment for chronic pain before surgery
  • Psychiatric or neurological disorders
  • Cannot fluently read or speak English
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Local infiltration with liposomal bupivacaine

    Patients randomized into the liposomal bupivacaine group will receive anesthesia and undergo standard posterior spinal fusion surgery. The local infiltration would occur in a single stage, after instrumentation and correction maneuver is performed, just prior to closure of the deep fascial layer. The dose would be injected via multiple small volume injections into the paraspinal musculature, spaced approximately 1 cm apart.

    Drug: Bupivacaine liposome injectable suspension

  • Active comparator
    Local infiltration with 0.25% bupivacaine with epinephrine

    Patients randomized into the 0.25% bupivacaine with epinephrine group will receive anesthesia and undergo standard posterior spinal fusion surgery under the same condition as the intervention group with one exception: the local infiltration will be made up of equal volume of 0.25% bupivacaine with epinephrine. The equal volume of 0.25% bupivacaine with epinephrine will be used in the exact same administration technique as the liposomal bupivacaine group, involving multiple small-volume injections to the paraspinal musculature spaced approximately 1 centimeter apart.

    Drug: Bupivacaine Hydrochloride and Epinephrine Injection

Interventions

  • DrugLiposomal BupivacaineStudies of Liposomal BupivacaineLiposomal Bupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    EXPAREL is a milky white too off-white aqueous suspension available as single-dose vials. Each mL contains 13.3 mg of bupivacaine, which is contained in multivesicular liposomes.

    Also known as: EXPAREL

  • DrugBupivacaine Hydrochloride and Epinephrine Injection

    Drug pages: BupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EpinephrineStudies of EpinephrineEpinephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sensorcaine-MPF with Epinephrine 1:200,000 is a clear, colorless to slightly yellow solution available as single-dose vials. Each mL contains bupivacaine hydrochloride, 0.005 mg epinephrine, and 0.5 mg sodium metabisulfite (antioxidant), and 0.2 mg anhydrous citric acid (stabilizer).

    Also known as: Sensorcaine-MPF with Epinephrine 1:200,000

06

What researchers measure

Primary outcomes

  1. Total amount of morphine equivalents per kilogram

    Total amount of morphine equivalents per kilogram during the first 72 hours postoperatively.

    Time frame: 72 hours postoperatively

Secondary outcomes

  1. Numeric Rating Scale (NRS) pain scores

    The average Numeric Rating Scale pain score (on a scale of 0-10) during the first 72 hours postoperatively will be computed from at most six values typically obtained every four to six hours following surgery. The higher the score, the higher the experienced pain of the individual.

    Time frame: 72 hours postoperatively

  2. Pain, functional ability, and mental health scores

    SRS-22r scores at 1-, 6-, 12-, and 24-months post-operatively. The Scoliosis Patient Questionnaire Version 22r (SRS-22r) is a patient-reported outcome instrument with 22 questions that evaluates the impact of scoliosis and surgery on patient quality of life. Scores from the SRS-22r are compiled into five domain scores: function, pain, self-image, mental health, and satisfaction with management of scoliosis. Each domain score is reported on a scale form 1-5. The lower the score, the worse the outcome.

    Time frame: 1-, 6-, 12-, and 24-months postoperatively

07

Study locations

1 of 1 sites recruiting
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Sara Olenich, MS · Contactsara.olenich@childrens.harvard.edu · (617) 355-6000
    • Craig Birch, MD · Principal investigator
    • Daniel Hedequist, MD · Sub investigator
    • Timothy Hresko, MD · Sub investigator
    • Grant Hogue, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 24 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 24 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
Jun 24, 2024
StartActual
Aug 15, 2025
Primary completionEst.
Aug 15, 2027
CompletionEst.
Aug 31, 2028
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06471348
Responsible party
Craig Birch (Instructor of Orthopedic Surgery, Harvard Medical School, Boston Children's Hospital) — Principal investigator
First posted
Jun 24, 2024
Start date
Aug 15, 2025
Primary completion
Aug 15, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 22, 2025

Study contacts

Sara Olenich, MS
Contact
sara.olenich@childrens.harvard.edu
(617) 355-6000
Mikayla Flowers, MA
Contact
Mikayla.Flowers@childrens.harvard.edu
Craig Birch, MD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion